Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
89%(8 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
7
70%
Ph phase_3
2
20%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 27 (70.0%)
Phase 32 (20.0%)

Trials by Status

completed990%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_2

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

NCT03732534
completedphase_2

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02679079
completedphase_2

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

NCT02581865
completedphase_3

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

NCT02405091
completedphase_2

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

NCT01688037
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03732534Phase 2

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Terminated
NCT02679079Phase 2

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Completed
NCT02581865Phase 2

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Completed
NCT02405091Phase 3

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Completed
NCT01688037Phase 2

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Completed
NCT01393600Phase 2

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Completed
NCT01733121Phase 2

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Completed
NCT02274558Phase 3

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Completed
NCT02256475Phase 1

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Completed
NCT01267188Phase 2

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10